Effect of Dupilumab on Nasal Epithelial Barrier Function in Patients With CRSwNP

NCT06398873 · clinicaltrials.gov ↗

RECRUITING

Status

80

Enrollment

OTHER

Sponsor class

Conditions

Chronic Rhinosinusitis With Nasal Polyps
Chronic Rhinosinusitis Without Nasal Polyps

Interventions

DRUG: Dupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT]

Sponsor

Medical University of Vienna